Physician profile
Daniel W Chang
NPI 1194761841
$11,633.57
in general payments reported to CMS, 2019-2025
29 companies · $3,074 in 2025
The $3,074 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $725 · 2021: $5,324 · 2022: $486 · 2023: $555 · 2024: $907 · 2025: $3,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,517 · Travel and Lodging: $2,006 · Education: $13.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.50 |
| Travel and Lodging | $2,005.79 |
| Education | $13.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,557.25 | 2021-2025 | Qulipta, Ubrelvy |
| Penumbra, INC. | $1,490.29 | 2025 | Penumbra System |
| Allergan, INC. | $1,216.52 | 2020-2021 | |
| Medical Device Business Services, INC. | $630.08 | 2025 | Trufill |
| Pfizer INC. | $569.97 | 2019-2025 | |
| Amgen INC. | $530.74 | 2019-2024 | Uplizna |
| Mdd US Operations, LLC | $283.19 | 2019-2024 | Gocovri, Apokyn |
| Genzyme Corporation | $249.54 | 2019 | |
| Stryker Corporation | $223.03 | 2024 | Target |
| Depuy Synthes Sales INC. | $144.50 | 2025 | Embotrap |
| Avanir Pharmaceuticals, INC. | $96.57 | 2019-2021 | |
| Ucb, INC. | $89.21 | 2021 | |
| Sumitomo Pharma America, INC. | $81.56 | 2024 | Aptiom |
| Biohaven Pharmaceuticals, INC. | $64.18 | 2021 | |
| Medtronic, INC. | $59.84 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $54.80 | 2023 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $44.78 | 2019-2020 | |
| Biogen, INC. | $43.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.96 | 2022 | |
| Assertio Therapeutics, INC. | $26.68 | 2019 | |
| Horizon Therapeutics Plc | $20.18 | 2021 | |
| Eisai INC. | $17.91 | 2024 | |
| Scilex Pharmaceuticals INC. | $17.65 | 2024 | |
| Acorda Therapeutics, INC | $16.97 | 2020 | |
| Lundbeck LLC | $15.60 | 2024 | Rexulti |
| Alexion Pharmaceuticals, INC. | $15.59 | 2025 | Ultomiris |
| Route 92 Medical, INC. | $15.10 | 2025 | |
| Boston Scientific Corporation | $15.00 | 2023 | Lux-Dx Insertable Cardiac Monitor |
| Arbor Pharmaceuticals, INC. | $14.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.